Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018-Reference-Cited by-同舟云学术

Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018

Published:2019-01-17 Issue:3 Volume:24 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Takashita Emi¹,Kawakami Chiharu²,Morita Hiroko¹,Ogawa Rie¹,Fujisaki Seiichiro¹,Shirakura Masayuki¹,Miura Hideka¹,Nakamura Kazuya¹,Kishida Noriko¹,Kuwahara Tomoko¹,Mitamura Keiko³,Abe Takashi⁴,Ichikawa Masataka⁵,Yamazaki Masahiko⁶,Watanabe Shinji¹,Odagiri Takato¹,

Affiliation:

1. Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan

2. Yokohama City Institute of Public Health, Kanagawa, Japan

3. Eiju General Hospital, Tokyo, Japan

4. Abe Children’s Clinic, Kanagawa, Japan

5. Ichikawa Children’s Clinic, Kanagawa, Japan

6. Zama Children’s Clinic, Kanagawa, Japan

Abstract

The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza virus infection in Japan in February 2018. Two influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic subunit (PA) were detected in baloxavir-treated children in December 2018. This mutation is known to confer reduced susceptibility to baloxavir, and the two mutant viruses exhibited 76- and 120-fold reduced susceptibility to baloxavir.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference8 articles.

1. Influenza antivirals currently in late-phase clinical trial.;Koszalka;Influenza Other Respir Viruses,2017

2. Baloxavir marboxil for uncomplicated influenza in adults and adolescents.;Hayden;N Engl J Med,2018

3. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.;Omoto;Sci Rep,2018

4. Susceptibility of influenza viruses to the novel cap-dependent endonuclease inhibitor baloxavir marboxil.;Takashita;Front Microbiol,2018

5. Influenza virus susceptibility and resistance to oseltamivir.;Aoki;Antivir Ther,2007

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detection of influenza A(H3N2) viruses with polymerase acidic subunit substitutions after and prior to baloxavir marboxil treatment during the 2022–2023 influenza season in Japan;Antiviral Research;2024-09

2. Broad-spectrum activity against mosquito-borne flaviviruses achieved by a targeted protein degradation mechanism;Nature Communications;2024-06-19

3. Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial;The Lancet Infectious Diseases;2024-05

4. The impact of PA/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza A viruses to baloxavir;Archives of Virology;2024-01-12

5. The generation of hemagglutinin monoclonal antibodies against H9N2 influenza virus;Animal Diseases;2023-11-27